iCell Gene Therapeutics
iCell Gene Therapeutics is a clinical-stage, fully integrated cell therapy company with a robust pipeline of novel cellular therapies for autoimmune diseases and cancer.
ICG 318, iCell gene’s lead program, is a BCMA-CD19-IL-15/ IL-15Rα sushi compound CART cell therapy being investigated in an ongoing Phase I/ II clinical trial in Systemic Lupus Erythematosus/ Lupus Nephritis. Initial IIT data demonstrated 92% complete, medication free remission with all elevated autoantibodies eliminated and no relapse at a median follow up of over 470 days.
The iCell Gene portfolio also includes a number of additional promising clinic stage assets including a CD33/ CLL1 compound CAR T being studied in AML, a CD7 CAR T being studied in T-cell NHL and T-ALL and a DLL3 dual epitope, compound CAR T being studied in SCLC.
iCell Gene has an optimal infrastructure with fully integrated US capabilities from research and development through to vector and drug product manufacturing, along with a technical operations and clinical IIT arm in China which enables us to rapidly develop and clinically investigate our novel cell therapies.
iCell Gene has also developed a novel and proprietary process for manufacturing vector from a master cell bank that allows us to rapidly produce high quality vector with significant cost and time savings.
